Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of SAL003 added to statin therapy in hypercholesterolemia and mixed hyperlipidemia
CTR20233652Phase 3Completed
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypercholesterolemia and combined dyslipidaemia comparing SAL003 + statin therapy with Placebo + statin therapy (2 arms). Primary endpoint: Percent change from baseline in low-density lipoprotein cholesterol at Week 24. Started Nov 2023; status: completed.
02
Drugs
SAL003
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on CTR20233652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233652.